A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Autor:	Krepler C; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Sproesser K; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Brafford P; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Beqiri M; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Garman B; Department of Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Xiao M; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Shannan B; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Watters A; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Perego M; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Zhang G; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Vultur A; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Yin X; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Liu Q; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA., Anastopoulos IN; Department of Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Wubbenhorst B; Department of Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Wilson MA; Department of Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Xu W; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Karakousis G; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Feldman M; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Xu X; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Amaravadi R; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Gangadhar TC; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Elder DE; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Haydu LE; MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA., Wargo JA; MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA., Davies MA; MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA., Lu Y; MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA., Mills GB; MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA., Frederick DT; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Barzily-Rokni M; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Hoon DS; Translational Molecular Medicine, John Wayne Cancer Institute, Santa Monica, CA 90404, USA., Guarino M; Helen F. Graham Cancer Center at Christiana Care, Newark, DE 19713, USA., Bennett JJ; Helen F. Graham Cancer Center at Christiana Care, Newark, DE 19713, USA., Ryan RW; Helen F. Graham Cancer Center at Christiana Care, Newark, DE 19713, USA., Petrelli NJ; Helen F. Graham Cancer Center at Christiana Care, Newark, DE 19713, USA., Shields CL; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA 19107, USA., Terai M; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107., Sato T; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107., Aplin AE; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107., Roesch A; Department of Dermatology, University Duisburg-Essen, University Hospital Essen, 45147 Essen, Germany; German Consortium of Translational Cancer Research, Heidelberg, Germany., Darr D; Lineberger Cancer Center, University of North Carolina Chapel Hill, NC 27514, USA., Angus S; Lineberger Cancer Center, University of North Carolina Chapel Hill, NC 27514, USA., Kumar R; Glaxosmithkline, Collegeville, PA 19426, USA., Halilovic E; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Caponigro G; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Jeay S; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Wuerthner J; Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA., Walter A; Bayer Pharma AG, Berlin 13353, Germany., Ocker M; Bayer Pharma AG, Berlin 13353, Germany., Boxer MB; National Center for Advancing Translational Sciences, NIH, Rockville, MD 20850, USA., Schuchter L; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Nathanson KL; Department of Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Herlyn M; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA. Electronic address: herlynm@wistar.org.
Jazyk:	angličtina
Zdroj:	Cell reports [Cell Rep] 2017 Nov 14; Vol. 21 (7), pp. 1953-1967.
DOI:	10.1016/j.celrep.2017.10.021
Abstrakt:	Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitate further advancements through pre-clinical in vivo modeling, we have established 459 patient-derived xenografts (PDX) and live tissue samples from 384 patients representing the full spectrum of clinical, therapeutic, mutational, and biological heterogeneity of melanoma. PDX have been characterized using targeted sequencing and protein arrays and are clinically annotated. This exhaustive live tissue resource includes PDX from 57 samples resistant to targeted therapy, 61 samples from responders and non-responders to immune checkpoint blockade, and 31 samples from brain metastasis. Uveal, mucosal, and acral subtypes are represented as well. We show examples of pre-clinical trials that highlight how the PDX collection can be used to develop and optimize precision therapies, biomarkers of response, and the targeting of rare genetic subgroups. (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu